Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STX107 in Adults With Fragile X Syndrome
NCT01325740Phase 2Suspended
- Sponsor
- Seaside Therapeutics
- Start
- May 2011
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fenobam in Fragile X syndrome (FXS) (3 arms), sponsored by Seaside Therapeutics. Primary endpoint: Adverse events at 1 day. Started May 2011; status: suspended.
02
Drugs
fenobam
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT01325740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01325740.